Overview Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B Status: Completed Trial end date: 2007-01-01 Target enrollment: Participant gender: Summary This study is being conducted to compare the effectiveness and safety of telbivudine (LdT) and lamivudine in Chinese adults. Phase: Phase 3 Details Lead Sponsor: NovartisCollaborator: Novartis PharmaceuticalsTreatments: LamivudineTelbivudine